资讯
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...
Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...
Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...
The first step of setting up a new device starts with cleaning up your old phone. If you’re planning on trading in your old ...
17 小时
Health on MSNHow and Where To Get ZepboundMedically reviewed by Kelly Wood, MD Zepbound (tirzepatide) is a once-a-week injectable weight-loss medication. It helps ...
1 天
Zacks Investment Research on MSNRoche's Q1 Sales Increase Y/Y on Solid Performance of Key DrugsSwiss pharma giant Roche Holding AG RHHBY posted strong growth in the first quarter of 2025. Sales increased 7% year over year to CHF 15.4 billion and were up 6% at constant exchange rates (CER).
But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which ...
Without a carve-out for tariff exceptions for pharmaceuticals, prices will skyrocket for US patients, experts warn.
The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...
Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...
Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果